May/June 1997

Cancer Control Journal Vol 4, No 3, Supplement CME Pretest

In this supplement, the topic of current controversies in breast cancer is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 1 hour of Category I Continuing Medical Education

Complimentary CME Credits

Physicans can earn up to 1 credit hour of Category I for the Physican's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Eight successfully answered questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this supplement on controversies in breast cancer, clinicians will be expected to:

• be aware of progress in staging breast cancer,
  
• keep abreast of the status of hormonal and systemic treatments for breast cancer; and
  
• be familiar with the impact and use of the taxanes, either alone or in combination, in patients with breast cancer.

This program was planned in accordance with ACCME Essentials.
Release Date: May 1, 1997 Expiration Date: May 1, 1998

Pretest

1. What percentage of women who have axillary dissection for breast cancer will experience edema acutely in the ipsilateral arm?

a.10%

b. 20%

c. 40%

d. 60%

2. What is the probable optimum duration for tamoxifen given as an adjuvant for a T2, N0 ER-positive carcinoma of the breast?

a. 2 years

b. 5 years

c. 10 years

d. unknown

3. What percentage of complete remissions did Gianni and colleagues report for a combination of doxorubicin and paclitaxel used to treat metastatic breast cancer?

a. 5%

b. 20%

c. 30%

d. 40%